Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Lenvatinib, a multi-tyrosine kinase inhibitor that inhibits vascular endothelial growth factor and fibroblast growth factor receptors pathway, activated the immune response in tumor microenvironment. However, the combination of lenvatinib and anti-PD-1 has been reported in early phase studies. Hence...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wen-Chi, Lin, Tzu-Yuan, Chen, Ming‑Huang, Hung, Yi‑Ping, Liu, Chien-An, Lee, Rheun‑Chuan, Huang, Yi‑Hsiang, Chao, Yee, Chen, San-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288359/
https://www.ncbi.nlm.nih.gov/pubmed/35477812
http://dx.doi.org/10.1007/s10637-022-01248-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288359/
https://www.ncbi.nlm.nih.gov/pubmed/35477812
http://dx.doi.org/10.1007/s10637-022-01248-0

Ejemplares similares